⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL50602 | 0.72 | LMNA (0.40) | — | |
| SCHEMBL31046 | 0.69 | — | — | |
| SCHEMBL5909 | 0.69 | — | — | |
| SCHEMBL8527087 | 0.67 | — | — | |
| SCHEMBL30536998 | 0.67 | — | — | |
| SCHEMBL30022145 | 0.67 | — | — | |
| SCHEMBL8602873 | 0.67 | — | — | |
| SCHEMBL967037 | 0.67 | — | — | |
| SCHEMBL413049 | 0.67 | LMNA (0.35) | — | |
| SCHEMBL16130 | 0.67 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260035756-A1 | BIOLOGICAL TEST SAMPLING KIT | HEMODX AS (NO) | 2026-02-05 | — | — | US | claimed |
| EP-4569130-A1 | BIOLOGICAL TEST SAMPLING KIT | Hemodx AS (NO) | 2025-06-18 | — | — | EP | claimed |
| WO-2024033450-A1 | BIOLOGICAL TEST SAMPLING KIT | HEMODX AS (NO) | 2024-02-15 | — | — | WO | claimed |
| CN-114107204-B | System construction of brain glioma macrophage ligand | 中国人民解放军陆军军医大学第一附属医院 | 2023-10-27 | — | — | CN | claimed |
| CN-114107204-A | System construction of brain glioma macrophage ligand | 中国人民解放军陆军军医大学第一附属医院 | 2022-03-01 | — | — | CN | claimed |
| US-12590970-B2 | Use of amino acids to enhance signal in mass spectral analyses | REGENERON PHARMACEUTICALS, INC. (US) | 2026-03-31 | — | — | US | disclosed |
| US-20260035756-A1 | BIOLOGICAL TEST SAMPLING KIT | HEMODX AS (NO) | 2026-02-05 | — | — | US | disclosed |
| EP-4569130-A1 | BIOLOGICAL TEST SAMPLING KIT | Hemodx AS (NO) | 2025-06-18 | — | — | EP | disclosed |
| WO-2024033450-A1 | BIOLOGICAL TEST SAMPLING KIT | HEMODX AS (NO) | 2024-02-15 | — | — | WO | disclosed |
| US-20230417759-A1 | Use of Amino Acids to Enhance Signal in Mass Spectral Analyses | REGENERON PHARMACEUTICALS, INC. | 2023-12-28 | — | — | US | disclosed |
| CN-114107204-B | System construction of brain glioma macrophage ligand | 中国人民解放军陆军军医大学第一附属医院 | 2023-10-27 | — | — | CN | disclosed |
| US-20230037822-A1 | IMMUNE CELL RECEPTOR ANTIBODIES CONJUGATED TO HIGH AFFINITY SIGLEC-LIGANDS | THE SCRIPPS RESEARCH INSTITUTE (US) | 2023-02-09 | — | — | US | disclosed |
| EP-4088120-A1 | USE OF AMINO ACIDS TO ENHANCE SIGNAL IN MASS SPECTRAL ANALYSES | Regeneron Pharmaceuticals, Inc. (US) | 2022-11-16 | — | — | EP | disclosed |
| US-20160000894-A1 | IN VIVO EFFICACY OF NY-ESO-1 PLUS ADJUVANT | CSL LIMITED (AU) | 2016-01-07 | — | — | US | disclosed |
| US-20120171232-A1 | IN VIVO EFFICACY OF NY-ESO-1 PLUS ADJUVANT | LUDWIG INSTITUTE FOR CANCER RESEARCH | 2012-07-05 | — | — | US | disclosed |
| US-20070190072-A1 | In vivo efficacy of ny-eso-1 plus adjuvant | CSL LIMITED LUDWIG INSTITUTE FOR CANCER RESEARCH | 2007-08-16 | — | — | US | disclosed |
| WO-2005033278-A2 | IN VIVO EFFICACY OF NY-ESO-1 PLUS ISCOM | LUDWIG INSTITUTE FOR CANCER RESEARCH (US) | 2005-04-14 | — | — | WO | disclosed |